ANXA2 regulates the behavior of SGC-7901 cells

Meng-Yao Sun1, Rui-Huan Xing, Xiao-Jie Gao

  • 1The Lab of Tumor Molecular Cellular Biology, Shaanxi Normal University, Xi'an, Shaanxi,China

Insights

Annexin A2 (ANXA2) overexpression drives gastric cancer malignancy. Inhibiting ANXA2 in gastric cancer cells reduced proliferation and motility, suggesting ANXA2 as a potential gene therapy target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Annexin A2 (ANXA2) is implicated in tumor development.
  • The specific role of ANXA2 in gastric carcinoma remains unclear.

Purpose of the Study:

  • To investigate the function of ANXA2 in gastric cancer cell growth.
  • To evaluate ANXA2 as a potential therapeutic target for gastric carcinoma.

Main Methods:

  • ANXA2 expression was inhibited using siRNA in SGC-7901 gastric cancer cells.
  • Cell proliferation, cell cycle, apoptosis, and motility were assessed using MTT assay, flow cytometry, Hoechst 33342 staining, and wound healing assays.
  • Microstructural changes were observed via fluorescence microscopy, laser scanning confocal microscopy, and electron microscopy.

Main Results:

  • ANXA2 inhibition significantly decreased cell proliferation and motility, inducing G1 arrest.
  • Apoptosis was enhanced, though not significantly.
  • ANXA2 deletion led to reduced pseudopodia/filopodia, decreased F-actin and β-tubulin expression, and reappearance of contact inhibition.

Conclusions:

  • ANXA2 overexpression is crucial for maintaining gastric cancer cell malignancy.
  • ANXA2 presents a potential target for gene therapy in gastric carcinoma.